Skip to main content
Clinical Trials/NCT02555410
NCT02555410
Completed
Not Applicable

A Pivotal, Phase II Trial of Detecting Generalized Tonic-Clonic Seizures With a Seizure Detection and Warning System in Epilepsy Patients

Brain Sentinel1 site in 1 country11 target enrollmentJanuary 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Epilepsy
Sponsor
Brain Sentinel
Enrollment
11
Locations
1
Primary Endpoint
Test the function of the system including ability to acquire EMG signal, analyze and successfully transmit the analysis to the base station, and identify and transmit all alert conditions.
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

This is a phase III, pilot, prospective study of an Electromyography (EMG) based seizure detection system for detecting Generalized Tonic-Clonic Seizures (GTCS) in the home.

Detailed Description

The Brain Sentinel™ Seizure Detection and Warning System is intended for monitoring children and adults with a history or significant risk of generalized tonic-clonic seizures in the home or healthcare facilities, during the titration or withdrawal of anti-epileptic drugs, and for continuous monitoring (night time or any other time of day) of individuals due to their history or risk of generalized tonic-clonic seizures. The device will withstand activities of daily living including showers and sleep.

Registry
clinicaltrials.gov
Start Date
January 2013
End Date
July 7, 2017
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subject has a history of GTC seizures, either primary GTC or partial onset seizures with secondary generalization.
  • Male or female between the ages of 2-
  • Has an upper arm circumference which is adequate for proper fit of the EMG monitor (at least 14cm).
  • Be able to tolerate wearing the device on the upper arm.
  • If female and of childbearing potential, has a negative pregnancy test.
  • Can understand and sign written informed consent, or will have a parent or a legally authorized representative (LAR) who can do so, prior to the performance of any study assessments.
  • Subject and/or Primary Caregiver must be competent to follow all study procedures.
  • Is able to read, speak and understand English.

Exclusion Criteria

  • Does not have a documented history of generalized seizures.
  • The subject's upper arm circumference not adequate for proper fit of the EMG monitor (less than 14cm)
  • Pregnant female
  • Subject/Caregiver is unable to provide consent.
  • Subject/Caregiver is not competent to follow home study procedures.
  • The subject is homeless or in a home without a power supply.

Outcomes

Primary Outcomes

Test the function of the system including ability to acquire EMG signal, analyze and successfully transmit the analysis to the base station, and identify and transmit all alert conditions.

Time Frame: up to 1 month

The overall usability and technical features will be assessed through questionnaires and surveys as the Seizure Detection and Warning System will be used within a home setting.

Secondary Outcomes

  • Compare the accuracy of the EMG based system's log to the subject's seizure diary(up to one month)

Study Sites (1)

Loading locations...

Similar Trials